Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage For the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
Marketing Status OTC; Discontinued; Prescription
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 72189-243; 63187-213; 69097-859; 59349-0008; 70518-1191; 76282-209; 62135-572; 71335-1668; 71205-152
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Deafness neurosensory17.04.07.001; 04.02.01.0020.001411%Not Available
Death08.04.01.001--
Delirium19.13.02.0010.001411%
Dementia19.20.02.001; 17.03.01.0010.000706%Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.0010.001058%Not Available
Depression19.15.01.0010.008467%
Dermatitis23.03.04.0020.000706%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000706%Not Available
Dermatitis bullous23.03.01.0020.000706%
Dermatitis contact23.03.04.004; 12.03.01.040; 10.01.01.0030.001764%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.002470%
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.002117%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000706%Not Available
Disturbance in attention17.03.03.001; 19.21.02.0020.001058%
Dizziness24.06.02.007; 02.01.02.004; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.001764%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.0010.001058%
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.0010.001411%
Dysgeusia17.02.07.003; 07.14.03.0010.016581%
Dyspepsia07.01.02.0010.003881%
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Eczema23.03.04.0060.000706%
Embolism venous24.01.01.0030.000276%Not Available
Enterocolitis haemorrhagic24.07.02.006; 07.08.01.0070.000706%Not Available
Eosinophilia01.02.04.0010.004586%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages